Feeds:
Posts
Comments

Posts Tagged ‘metastatic prostate cancer’

NEW PROSTATE CANCER INFOLINK: How long have you got to live if your prostate cancer spreads after initial treatment?

We have been told that the median survival of a man diagnosed with metastatic prostate cancer today may be as much as 5-6 years, but actual data to support this belief are very hard to come by, writes Mike Scott. READ MORE>

Read Full Post »

CANCER CONSULTANTS.COM: A drug treatment called Bonefos (sodium clodronate) – that blocks the function of the cells which reabsorb bone – reduces the risk of death by 23% in men with metastatic prostate cancer, report UK researchers. READ MORE>

Read Full Post »

URO TODAY: Australian researchers have identified a novel transcription factor in metastatic prostate cancer designated IV07, which appears to be involved in the regulation and co-ordination of multiple cancer promoting pathways. READ MORE>

The identification of IV07 may provide an important new therapeutic target in the prevention or treatment of metastatic disease and possibly may serve as a prognostic biomarker for cancer progression.

Read Full Post »

CANCER CONSULTANTS: Clodronate reduces the risk of death by 23% in men with metastatic prostate cancer, according to the results of a study published in The Lancet Oncology. Clodronate belongs to a class of drugs called bisphosphonates, which are used to treat or prevent bone complications. READ MORE>

Read Full Post »

JULY 29: URO TODAY: Analysis of an enzyme in men’s urine may provide a new way to diagnose metastatic prostate cancer, a new study suggests. READ MORE>

Read Full Post »

JULY 24: URO TODAY: Metastatic prostate cancer is an attractive target for radio-immunotherapy (RIT), as no effective therapies are available.

This review highlights the most important achievements within the last year in 3-D positron emission tomography (PET)/computed tomography (CT) and RIT. READ MORE>

Read Full Post »

JUNE 19: FORBES: Shares of Molecular Insight Pharma Inc rose 29 percent in pre-market trade a day after the bio-pharmaceutical company said its imaging agent, Trofex, had the potential to both detect and treat metastatic prostate cancer. READ MORE>

Read Full Post »

MAY 16: DRUGS.COM: Researchers claim to have found a way to better customise the treatment of prostate cancer. Four risk factors that can help predict how long men could survive with metastatic prostate cancer have been identified by researchers from the Duke Comprehensive Cancer Center, who say such information would help doctors individualise treatments. READ MORE>

Read Full Post »